Jump to ContentJump to Main Navigation
Show Summary Details

Radiology and Oncology

The Journal of Association of Radiology and Oncology

4 Issues per year

IMPACT FACTOR 2015: 1.736

SCImago Journal Rank (SJR) 2015: 0.631
Source Normalized Impact per Paper (SNIP) 2015: 0.968
Impact per Publication (IPP) 2015: 1.796

Open Access
See all formats and pricing
Volume 45, Issue 1 (Mar 2011)


Electrogene therapy with interleukin-12 in canine mast cell tumors

Darja Pavlin
  • Veterinary Faculty Ljubljana, University of Ljubljana, Ljubljana, Slovenia
/ Maja Cemazar
  • Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
  • College of Health Care Izola, University of Primorska, Izola, Slovenia
/ Andrej Cör
  • College of Health Care Izola, University of Primorska, Izola, Slovenia
/ Gregor Sersa
  • Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
/ Azra Pogacnik
  • Veterinary Faculty Ljubljana, University of Ljubljana, Ljubljana, Slovenia
/ Natasa Tozon
  • Veterinary Faculty Ljubljana, University of Ljubljana, Ljubljana, Slovenia
Published Online: 2010-09-22 | DOI: https://doi.org/10.2478/v10019-010-0041-9

Electrogene therapy with interleukin-12 in canine mast cell tumors

Background. Mast cell tumors (MCT) are the most common malignant cutaneous tumors in dogs with extremely variable biological behaviour. Different treatment approaches can be used in canine cutaneous MCT, with surgical excision being the treatment of choice. In this study, electrogene therapy (EGT) as a new therapeutic approach to canine MCTs, was established.

Materials and methods. Eight dogs with a total of eleven cutaneous MCTs were treated with intratumoral EGT using DNA plasmid encoding human interleukin-12 (IL-12). The local response to the therapy was evaluated by repeated measurements of tumor size and histological examination of treated tumors. A possible systemic response was assessed by determination of IL-12 and interferon- γ (IFN-γ) in patients' sera. The occurence of side effects was monitored with weekly clinical examinations of treated animals and by performing basic bloodwork, consisting of the complete bloodcount and determination of selected biochemistry parameters.

Results. Intratumoral EGT with IL-12 elicits significant reduction of treated tumors' size, ranging from 13% to 83% (median 50%) of the initial tumor volume. Additionally, a change in the histological structure of treated nodules was seen. There was a reduction in number of malignant mast cells and inflammatory cell infiltration of treated tumors. Systemic release of IL-12 in four patients was detected, without any noticeable local or systemic side effects.

Conclusions. These data suggest that intratumoral EGT with plasmid encoding IL-12 may be useful in the treatment of canine MCTs, exerting a local antitumor effect.

Keywords: electroporation; electrotransfection; electrogene therapy; mast cell tumors; IL-12; IFN-γ

  • Thamm DH, Vail DM. Mast Cell Tumors. In: Withrow SJ, Wail DM, editors. Withrow and MacEwen's small animal clinical oncology, 4th edn. St. Louis: Saunders; 2007. p. 402-16.

  • Maureen C, XinRu T, Benett P. Combination CCNU and Vinblastine chemotherapy for canine mast cell tumors: 57 cases. Vet Comp Onc 2009; 7: 196-206.

  • Cemazar M, Tamzali Y, Sersa G, Tozon N. Mir LM, Miklavcic D, et al. Electrochemotherapy in veterinary oncology. J Vet Intern Med 2008; 22: 826-31. [Web of Science] [Crossref] [PubMed]

  • Mir LM, Glass LF, Sersa G, Teissie J, Domenge C, Miklavcic D, et al. Effective treatment of cutaneous and subcutaneous malignant tumors by electrochemotherapy. Br J Cancer 1998; 77: 2336-42. [Crossref] [PubMed]

  • Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumors. Eur J Surg Oncol 2008; 34: 232-40. [Crossref] [PubMed]

  • Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 29: 371-87. [PubMed] [Crossref]

  • Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1982; 1: 841-5. [PubMed]

  • Mir LM. Nucleic acids electrotransfer-based gene therapy (electrogenetherapy): past, current, and future. Mol Biotechnol 2009; 43: 167-76. [Web of Science] [Crossref] [PubMed]

  • Cemazar M, Golzio M, Sersa G, Rols MP, Teissié J. Electrically-assisted nucleic acids delivery to tissues in vivo: where do we stand? Curr Pharm Des 2006; 12: 3817-25. [PubMed]

  • Heller LC, Heller R. In vivo electroporation for gene therapy. Hum Gene Ther 2006; 17: 890-7. [Crossref] [PubMed]

  • Fewell JG, MacLaughlin F, Mehta V, Gondo M, Nicol F, Wilson E, et al. Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation. Mol Ther 2001; 3: 574-83. [PubMed] [Crossref]

  • Draghia-Akli R, Hahn KA, King GK, Cummings KK, Carpenter RH. Effects of plasmid-mediated growth hormone-releasing hormone in severely debilitated dogs with cancer. Mol Ther 2002; 6: 830-6. [Crossref]

  • Pavlin D, Tozon N, Sersa G, Pogacnik A, Cemazar M. Efficient electrotransfection into canine muscle. Technol Cancer Res Treat 2008; 7: 45-54. [PubMed]

  • Chou PC, Chuang TF, Jan TR, Gion HC, Huang YC, Lei HJ, et al. Effects of immunotherapy of IL-6 and IL-5 plasmids on transmissible veneral tumor in beagles. Vet Immunol Immunopathol 2009; 130: 25-34. [Crossref] [Web of Science]

  • Chuang, TF, Lee SC, Liao KW, Hsiao YW, Lo CH, Chiang BL, et al. Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model. Int J Cancer 2009; 125: 698-707. [Crossref]

  • DelVecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13: 4677-85. [Crossref] [Web of Science]

  • Heinzerling LM, Feige K, Rieder S, Akens MK, Dummer R, Stranzinger G, et al. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med 2001; 78: 692-702. [Crossref]

  • Siddiqui F, Li C-Y, LaRue SM, Poulson JM, Avery PR, Pruitt AF, et al. A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas. Mol Cancer Ther 2007; 6: 380-9. [Crossref] [Web of Science]

  • Kamensek U, Sersa G. Targeted gene therapy in radiotherapy. Radiol Oncol 2008; 42: 115-35. [Web of Science]

  • Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896-903.

  • Cemazar M, Jarm T, Sersa G. Cancer Electrogene Therapy with Interleukin-12. Cur Gene Ther 2010; 10: 300-11. [Crossref]

  • Patnaik AK, Ehler WY, MacEwen EG. Canine cutaneous mast cell tumors: morphological grading and survival in 83 dogs. Vet Pathol 1984; 21: 469-74.

  • Buettner M, Belke-Louis G, Rziha HJ, McInnes C, Kaaden OR. Detection, cDNA cloning and sequencing of canine interleukin 12. Cytokine 1998; 10: 241-8.

  • Phillips BS, Padilla ML, Dickerson EB, Lindstrom MJ, Helfand SC. Immunostimulatory effects of human recombinant interleukin-12 on peripheral blood mononuclear cells from normal dogs. Vet Immunol Immunopathol 1999; 70: 189-201. [Crossref]

  • Tamzali Y, Couderc B, Rols MP, Golzio M, Teissie J. Equine cutaneous tumors treatment by electro-chemo-immuno-therapy. In: Jarm T, Kramar P, Zupanic A, editors. IFBME proceedings, vol 16. New York: Springer; 2007. p. 610-3.

  • Rakhmilevich AL, Timmins JG, Janssen K, Pohlmann EL, Sheehy MJ, Yang NS. Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J Immunother 1999; 22: 135-44. [Crossref]

  • Li S, Zhang L, Torrero M, Cannon M, Barret R. Administration route- and immune cell activation-dependant tumor eradication by IL-12 electrotransfer. Mol Ther 2005; 12: 942-9. [Crossref]

  • Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 2002; 5: 668-75. [Crossref]

  • Pavlin D, Cemazar M, Kamensek U, Tozon N, Pogacnik A, Sersa G. Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma. Cancer Biol Ther 2009; 8: 2114-22. [Web of Science] [Crossref]

  • Tevz G, Kranjc S, Cemazar M, Kamensek U, Coer A, Krizan M, et al. Controlled systemic release of interleukin-12 after gene electrotransfer to muscle for cancer gene therapy alone or in combination with ionizing radiation in murine sarcomas. J Gene Med 2009; 11: 1125-37. [Crossref] [Web of Science]

  • Lucas ML, Heller R. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. DNA Cell Biol 2003; 22: 755-63. [Crossref]

  • Lee SC, Wu CJ, Wu PY, Huang YL, Wu CW, Tao MH. Inhibition of established subcutaneous and metastatic murine tumors by intramuscular electroporation of the interleukin-12 gene. J Biomed Sci 2003; 10: 73-86. [Crossref]

  • Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single dose interleukin 12 exposure on interleukin-12 associated toxicity and interferon-gamma production. Blood 1997; 90: 2541-8.

  • Heller L, Merkler K, Westover J, Cruz Y, Coppola D, Benson K, et al. Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model. Clin Cancer Res 2006; 12: 3177-83. [Crossref]

About the article

Published Online: 2010-09-22

Published in Print: 2011-03-01

Citation Information: Radiology and Oncology, ISSN (Online) 1581-3207, ISSN (Print) 1318-2099, DOI: https://doi.org/10.2478/v10019-010-0041-9. Export Citation

This content is open access.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

M. Cemazar, J. Ambrozic Avgustin, D. Pavlin, G. Sersa, A. Poli, A. Krhac Levacic, N. Tesic, U. Lampreht Tratar, M. Rak, and N. Tozon
Veterinary and Comparative Oncology, 2016, Page n/a
B Markelc, G Tevz, M Cemazar, S Kranjc, J Lavrencak, B Zegura, J Teissie, and G Sersa
Gene Therapy, 2012, Volume 19, Number 3, Page 312
Ursa Lampreht, Urska Kamensek, Monika Stimac, Gregor Sersa, Natasa Tozon, Masa Bosnjak, Andreja Brozic, Geraldo Gileno de Sá Oliveira, Takayuki Nakagawa, Kohei Saeki, and Maja Cemazar
The Journal of Membrane Biology, 2015
Jeffry Cutrera, Glenn King, Pamela Jones, Kristin Kicenuik, Elias Gumpel, Xueqing Xia, and Shulin Li
Journal of Cellular and Molecular Medicine, 2015, Volume 19, Number 3, Page 664
Gerardo Claudio Glikin and Liliana María Elena Finocchiaro
The Scientific World Journal, 2014, Volume 2014, Page 1
Sophie Chabot, Sandrine Pelofy, Justin Teissié, and Muriel Golzio
Pharmaceuticals, 2013, Volume 6, Number 4, Page 510
Masa Bosnjak, Beatriz Canals Lorente, Ziva Pogacar, Vesna Makovsek, and Maja Cemazar
The Journal of Membrane Biology, 2014, Volume 247, Number 5, Page 421
L Heller, V Todorovic, and M Cemazar
Cancer Gene Therapy, 2013, Volume 20, Number 12, Page 695
Ales Sedlar, Simona Kranjc, Tanja Dolinsek, Maja Cemazar, Andrej Coer, and Gregor Sersa
BMC Cancer, 2013, Volume 13, Number 1, Page 38
Elisabeth Bellard, Bostjan Markelc, Sandrine Pelofy, François Le Guerroué, Gregor Sersa, Justin Teissié, Maja Cemazar, and Muriel Golzio
Journal of Controlled Release, 2012, Volume 163, Number 3, Page 396
Jeong-Im Sin, Jae-Bok Park, In Hee Lee, Daehan Park, Youn Seok Choi, Jongseon Choe, and Esteban Celis
Cancer Immunology, Immunotherapy, 2012, Volume 61, Number 10, Page 1671

Comments (0)

Please log in or register to comment.
Log in